CEPI

VisMederi plays a key role within the Coalition for Epidemic Preparedness Innovations (CEPI) centralized laboratories network (CLN), the world's largest network dedicated to standardizing the evaluation of vaccine candidates against epidemics and pandemics. Within the global research group, VisMederi collaborates with the network’s partner laboratories to use harmonized reagents and shared protocols to support the standardized evaluation of vaccine candidates. VisMederi's collaboration with CEPI builds on the experience gained during the COVID-19 pandemic, when the organization was selected as one of the laboratories in CEPI's CLN to support the standardized assessment and comparison of immune responses to COVID-19 vaccine candidates. Today, VisMederi's serves as reference laboratory for Influenza and Mpox vaccine program, supporting the generation of robust and comparable immunogenicity data across sites and studies. For H5N8 influenza, VisMederi's test portfolio includes serological methods commonly used for vaccine licensure, including HAI, SRH, and microneutralization. For Mpox, VisMederi's test portfolio includes neutralization tests against multiple strains. Launched in 2020, CEPI's network of centralized laboratories has expanded to support vaccine developers across multiple pathogens and geographies. This work contributes to global preparedness efforts aimed at accelerating the development of vaccines for future epidemic and pandemic threats.
https://cepi.net/

Date:

18 Giugno 2026

Category:

VisMederi plays a key role within the Coalition for Epidemic Preparedness Innovations (CEPI) centralized laboratories network (CLN), the world’s largest network dedicated to standardizing the evaluation of vaccine candidates against epidemics and pandemics. Within the global research group, VisMederi collaborates with the network’s partner laboratories to use harmonized reagents and shared protocols to support the standardized evaluation of vaccine candidates.

VisMederi’s collaboration with CEPI builds on the experience gained during the COVID-19 pandemic, when the organization was selected as one of the laboratories in CEPI’s CLN to support the standardized assessment and comparison of immune responses to COVID-19 vaccine candidates.

Today, VisMederi’s serves as reference laboratory for Influenza and Mpox vaccine program, supporting the generation of robust and comparable immunogenicity data across sites and studies. For H5N8 influenza, VisMederi’s test portfolio includes serological methods commonly used for vaccine licensure, including HAI, SRH, and microneutralization. For Mpox, VisMederi’s test portfolio includes neutralization tests against multiple strains.

Launched in 2020, CEPI’s network of centralized laboratories has expanded to support vaccine developers across multiple pathogens and geographies. This work contributes to global preparedness efforts aimed at accelerating the development of vaccines for future epidemic and pandemic threats.